Our results suggest that the confirmation of diagnosis of FH is a barrier to FH care; however, its importance in comparison to other major barriers such as managing statin-associated muscle symptoms (real or perceived), clinician and patient knowledge gaps related to FH care, access to medications such as PCSK9 inhibitors, among others is unknown. Here, PCSK9 is linked to familial hyperaldosteronism.